Jefferies analyst Matthew Taylor initiated coverage of Shoulder Innovations (SI) with a Buy rating and $19 price target The firm says the company is gaining share in the large and growing shoulder market. Shoulder Innovations’s “superior” clinical data and efficiency advantages “give it the right to win,” the analyst tells investors in a research note. Jefferies believes the company can post over 30% annual revenue growth through 2028.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SI:
- Shoulder Innovations initiated with an Overweight at Piper Sandler
- Strong Buy Rating for Shoulder Innovations, Inc. Driven by Market Leadership and High Growth Potential
- Buy Rating for Shoulder Innovations, Inc.: Strong Growth Potential in Shoulder Replacement Market
- Shoulder Innovations initiated with a Buy at Goldman Sachs